iBio (NYSE:IBIO) Trading Up 4% – Time to Buy?

iBio, Inc. (NYSE:IBIO) was up 4% during mid-day trading on Monday . The stock traded as high as $3.18 and last traded at $3.13. Approximately 339,291 shares changed hands during trading, an increase of 26% from the average daily volume of 269,713 shares. The stock had previously closed at $3.01.

iBio Stock Performance

The business’s 50 day simple moving average is $2.65 and its two-hundred day simple moving average is $2.37. The company has a quick ratio of 3.37, a current ratio of 3.37 and a debt-to-equity ratio of 0.04.

iBio (NYSE:IBIO) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.46) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.46). Equities research analysts predict that iBio, Inc. will post -1.74 EPS for the current year.

Insider Activity

In related news, Director David Arkowitz purchased 18,382 shares of the business’s stock in a transaction on Friday, January 10th. The stock was acquired at an average price of $2.72 per share, with a total value of $49,999.04. Following the purchase, the director now directly owns 18,382 shares in the company, valued at approximately $49,999.04. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.58% of the company’s stock.

About iBio

iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.